Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma

29 septiembre 2014

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data.